Every material Form 8-K Xylem filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xylem reported third-quarter 2025 revenue of $2.3 billion, up 8% on a reported basis and 7% organically, and reported diluted EPS of $0.93, up 4%. Adjusted EPS rose 23% to $1.37, and the company raised its full-year 2025 revenue and adjusted EPS guidance, which matters to shareholders because it reflects higher expected earnings for the year.
Q3 2025 revenue was $2.3 billion, up 8% reported and 7% organic; net income attributable to Xylem was $227 million
Q3 2025 EPS was $0.93 reported, up 4%, and $1.37 adjusted, up 23% from $1.11
Full-year 2025 revenue guidance is about $9.0 billion, up 5% to 6% reported versus 4% to 5% previously
Full-year 2025 adjusted EPS guidance is $5.03 to $5.08, up from the previous $4.70 to $4.85
Xylem reported second-quarter 2025 revenue of $2.3 billion, up 6% on both reported and organic bases, and earnings per share of $0.93, up 16%. The company raised its full-year 2025 revenue and adjusted earnings per share guidance, which matters to shareholders because both headline measures improved and the outlook was lifted.
Q2 2025 revenue was $2.3 billion, up 6% on reported and organic bases.
Q2 net income attributable to Xylem was $226 million, or $0.93 per share, up 16%; adjusted EPS was $1.26, also up 16%.
Full-year 2025 adjusted EPS guidance was raised to $4.70 to $4.85 from $4.50 to $4.70.
Full-year 2025 revenue is now forecast at about $8.9 to $9.0 billion, up about 4 to 5% on a reported basis, versus 1 to 2% previously.
Xylem reported fourth-quarter 2024 revenue of $2.3 billion, up 7%, and full-year revenue of $8.6 billion, up 16% on a reported basis and 6% organically. Q4 reported EPS was $1.34 (up 22%) and adjusted EPS was $1.18 (up 19%); reported results include a non-recurring gain on remeasurement of its previously held Idrica equity interest. The company guided 2025 revenue of about $8.6 to $8.7 billion and adjusted EPS of $4.50 to $4.70, and declared a $0.40 quarterly dividend, up 11%.
Q4 2024 revenue $2.3 billion, up 7% on a reported and organic basis; orders $2.2 billion, up 7%
Q4 adjusted EPS $1.18, up 19%; reported EPS $1.34, up 22%, including a non-recurring Idrica remeasurement gain
2025 guidance: revenue of about $8.6 to $8.7 billion, adjusted EBITDA margin of 21.3% to 21.8%, adjusted EPS of $4.50 to $4.70
First-quarter dividend of $0.40 per share, up 11%, payable March 19, 2025 to holders of record as of February 18, 2025
Xylem said its fourth-quarter and full-year 2024 results will be largely in line with or above its prior guidance, and that management committed on January 28, 2025 to a restructuring plan with workforce reductions across all businesses and functions. The company expects pre-tax charges of $95 million to $115 million, mostly in 2025, which will weigh on reported profit while the cuts aim to streamline the organization.
Q4 and full-year 2024 results expected to be largely in line with or above guidance given October 31, 2024
Restructuring committed January 28, 2025, with workforce reductions across all businesses and functions
Pre-tax charges of approximately $95 million to $115 million, primarily in 2025, including about $19 million in Q4 2024
Most workforce reductions expected in fiscal 2025, with some in 2026, subject to local laws
Xylem director Jeanne Beliveau-Dunn told the board on January 10, 2025 that she will not seek re-election at the 2025 annual meeting of shareholders. She will remain on the board until that meeting, and the company says the decision was not due to any disagreement over operations, policies or practices. The board will shrink to nine members when she departs.
Jeanne Beliveau-Dunn notified the board on January 10, 2025 of her decision not to stand for re-election.
She will continue to serve as a director until the 2025 annual meeting of shareholders.
The filing states her decision was not due to any disagreement with the company or the board.
Board size will be reduced to nine members effective with her departure.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xylem filing is on SEC EDGAR ↗. 8-K briefs of other companies →